AstraZeneca Pharmaceuticals

AstraZeneca Pharmaceuticals
Share

New sub-analysis to be presented at the European Society of Cardiology (ESC) congress provides additional evidence of cardiovascular (CV) benefits associated with longer-term use of Brilinta 24 August 2017 AstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk reduction...

Lynparza’s new tablet formulation approved as maintenance treatment for women
with platinum-sensitive recurrent ovarian cancer regardless of BRCA-mutation status Lynparza tablets also indicated in BRCA-mutated ovarian cancer beyond the third-line setting Newly-approved tablet formulation means improved patient convenience 17 August 2017...

Fourth Breakthrough Therapy Designation for an AstraZeneca New Oncology medicine in three years 31 July 2017 AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Imfinzi (durvalumab) for the treatment of patients...

Imfinzi plus tremelimumab combination did not meet a primary endpoint of progression-free survival compared to chemotherapy The MYSTIC trial continues as planned to assess the additional primary endpoints of overall survival for Imfinzi monotherapy and for the Imfinzi plus tremelimumab combination 27 July 2017 AstraZeneca and MedImmune, its global...

Tagrisso met the primary endpoint, demonstrating a statistically-significant and clinically-meaningful progression-free survival benefit in 1st-line EGFRm non-small cell lung cancer compared to current standard-of-care treatment 27 July 2017 AstraZeneca today announced that the Phase III FLAURA trial showed a statistically-significant and...

Collaboration aims to maximise the potential of PARP and MEK inhibitors in combination with PD-L1/PD-1 medicines, based on growing scientific evidence that these combinations offer new potential for the treatment of a range of tumour types AstraZeneca and Merck will independently develop and commercialise Lynparza and potential medicine...

CHMP positive recommendation is based on Phase III data demonstrating a 20% reduction in risk of disease worsening or death over anastrozole 23 June 2017 AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing...

Comprehensive updated analysis provides valuable evidence on the safety profile of Farxiga, including no imbalance in lower-limb amputations New analyses from CVD-REAL examine reductions in CV events for SGLT-2 inhibitors, including Farxiga in patients with and without CV disease versus DPP-4 inhibitors 12 June 2017 AstraZeneca presented new data...

Updated safety data on risk-benefit profile of Farxiga (dapagliflozin), three new analyses from the landmark CVD-REAL study, including Farxiga vs DPP-4 inhibitors, and a late-breaking oral presentation reveal further CV evidence across a broad population of patients with type-2 diabetes Data from DURATION-7 and DURATION-8 evaluating efficacy and...

OlympiAD was the first positive Phase III trial to evaluate the efficacy and safety of a PARP inhibitor beyond ovarian cancer Lynparza tablets reduced risk of disease worsening or death by 42% The overall safety profile was consistent with previous trials of Lynparza 4 June 2017 AstraZeneca today presented positive results from its Phase III...